Prognostic analysis indicated that GM-CSF exhibited a significant association with a poor prognosis in only TNBC patients, without prognostic relevance in total breast cancer patients or patients with other molecular subtypes of breast cancer (Fig. 3D and Figure S1E). Here, CSF2 is linked to breast carcinoma.